ABSTRACT
INTRODUCTION
Congenital heart disease (CHD) occurs in approximately 6-12 per 1000 live births 1 . Advances in cardiac surgery and neonatal care have significantly increased survival rate of patients with CHD 2 ; however, these children frequently suffer from a broad spectrum of subsequent neurological deficits, including motor, cognitive and psychiatric morbidity [3] [4] [5] . In adolescents and young adults who have undergone a neonatal arterial switch operation for transposition of the great arteries, abnormal neurological and psycho-intellectual outcome has been related to alterations found on structural brain imaging 6 . Recent studies have found that a high proportion of fetuses with CHD already show signs of neurological damage before birth [7] [8] [9] [10] [11] , suggesting an early onset of the mechanisms leading to poorer neurodevelopment later in life. It has been hypothesized that abnormal heart morphology alters blood flow during fetal life, resulting in delivery of desaturated blood to the brain and thus causing a certain degree of cerebral hypoxia [11] [12] [13] [14] [15] [16] [17] . Nevertheless, prenatal signs of structural brain alterations have also been observed in CHD fetuses with a correct supply of oxygen to the brain, indicating that other abnormalities may be involved 11 . Angiogenesis is one of the regulatory pathways that control heart development. We have previously observed a decrease in serum levels of maternal placental growth factor (PlGF) in pregnancies with isolated major fetal heart defects, indicating that presence of CHD may have altered placental angiogenesis 18, 19 . Furthermore, higher expression of the antiangiogenic factor soluble fms-like tyrosine kinase-1 (sFlt-1) and the angiogenic factor vascular endothelial growth factor-A (VEGF-A) was observed in heart tissue and cord blood of fetuses with CHD compared with controls 19 . Fetal brain development is a complex and highly regulated process, and alterations in cerebral blood flow in CHD fetuses 17 may have deleterious effects in the developing brain. Studies performed in transgenic mouse models demonstrated that the expression of angiogenic factors, such as VEGF and PlGF, in prenatal brain tissue is critical for normal angiogenesis and, consequently, for correct cerebrovascular development [20] [21] [22] . We hypothesized that a dysregulation of angiogenesis occurs in fetuses with CHD that may lead to a higher risk of neurological impairment. In the present study, we examined the expression of antiangiogenic and angiogenic factors and of genes associated with chronic hypoxia in cerebral tissue samples from two distinct regions of the brain in euploid human fetuses with and without CHD.
METHODS
Fetal tissue samples were obtained at the time of autopsy following pregnancy termination during the period 2006-2011. All women provided written consent for the storage and use of fetal tissue samples for research purposes. All samples were obtained from the Fetal Tissue Bank of the Vall d'Hebron University Hospital (Barcelona, Spain) with appropriate ethics committee permission.
At autopsy, nine different regions of the brain were dissected and stored according to a standardized sampling protocol. The frontal cortex and the basal ganglia were selected for the present study because these regions control cognitive and motor abilities, respectively 23, 24 . However, due to technical difficulties in separating the basal ganglia from the hypothalamus, we could not rule out the possibility that basal ganglia samples also included small portions of the hypothalamus.
Expression profiles were evaluated of the antiangiogenic factor sFlt-1, the angiogenic factors VEGF-A and PlGF, and of the genes of hypoxia-inducible factor 1-alpha (HIF-1α) and hypoxia inducible factor 2-alpha (HIF-2α) associated with chronic hypoxia.
Study cohort
Study samples were obtained from fetuses with CHD after termination of pregnancy at 17-22 weeks' gestation. In all cases, termination of pregnancy was performed at the parents' request due to diagnosis of major congenital heart abnormality. In order to analyze the effect of cerebral hemodynamics according to the expected main patterns of placental (oxygenated, nutrient-rich) vs systemic (deoxygenated, nutrient-poor) mix of blood supply to the brain in different types of CHD, the CHD fetuses were stratified as follows, based on a previously published classification 25, 26 . CHD Group 1: expected low placental blood content, including severe left outflow tract obstruction with reversed flow in the aortic isthmus (and thus retrograde cerebral blood perfusion from the ductus arteriosus), and transposition of the great vessels (TGV) with aortic blood flow originating from the right ventricle; CHD Group 2: expected intermediate placental and systemic blood content owing to intracardiac shunts (septal defects, conotruncal defects other than TGV and complex CHD); CHD Group 3: expected high placental blood content, with brain perfusion originating from the left ventricle via a correctly formed aorta (right CHD), including pulmonary stenosis, tricuspid atresia, Ebstein's anomaly and pulmonary atresia.
Study samples were compared with samples of control fetuses without CHD. All control samples were obtained from fetuses without CHD following pregnancy termination at 17-22 weeks' gestation in otherwise healthy women. The reasons for termination of pregnancy in the control group were: maternal indications (n = 7), gastrointestinal malformation (n = 2), premature rupture of membranes (n = 1), vertebral anomaly (n = 1) and diaphragmatic hernia (n = 1).
RNA extraction and real-time polymerase chain reaction mRNA quantification
Fetal cerebral tissue samples from the frontal cortex or basal ganglia were used for total RNA extraction. Frozen tissue samples were triturated (less than 100 mg) using mortar and pestle, immersed in QIAzol Lysis Reagent (Qiagen, Hilden, Germany) and homogenized thoroughly (20-40 s) with a homogenizer (ULTRA-TURRAX T 10 basic disperser/homogenizer, IKA-Werke GmbH & Co. KG, Staufen, Germany). Total RNA was extracted and treated with DNase using the RNeasy ® Lipid Tissue (Qiagen) according to the manufacturer's protocol. RNA yield was quantified on a NanoDrop ND-2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). RNA (500 ng/reaction) was used for cDNA synthesis with random hexamer primers (RevertAid H minus first strand cDNA synthesis kit, Fermentas, St Leon-Rot, Germany). Inventoried (Table 1) and customized (sFlt-1) TaqMan Gene Expression Assays were obtained from Thermo Fisher Scientific. Sequences for sFlt-1 primers and probe were as follows: forward, 5 -GGGAAGAAATCCTCCAGAAGAAAGA-3 ; reverse, 5 -GAGATCCGAGAGAAAACAGCCTTT-3 ; probe, 5 -AGTGCTCACCTCTGATTG-3 27 . mRNA expression levels were normalized to the levels of human DNA-directed RNA polymerase II subunit A (assay ID Hs00172187_m1), and a control sample was used as a calibrator. Relative expression was calculated by the C t method, using Prism 7000 Sequence Detection System Software (v1.2.3) from Thermo Fisher Scientific.
Statistical analysis
Statistical analysis was performed using Prism version 5.0b software (GraphPad Software Inc., San Diego, CA, USA). Results are presented as mean ± standard error of the mean (SEM). Distribution of the variables was tested for normality using the D'Agostino-Pearson omnibus K 2 test. When the assumption of normality was satisfied, data were analyzed by Student's unpaired t-test; otherwise, the non-parametric Mann-Whitney U-test was used. Demographic data were analyzed using a two-sided t-test while gene expression was analyzed using a one-sided t-test. Significance was set at P ≤ 0.05.
RESULTS
Cerebral tissue was obtained and analyzed from 15 CHD and 12 control fetuses. No differences were observed in maternal and fetal characteristics between the CHD and control groups ( Table 2) .
CHD was detected by prenatal ultrasound and confirmed by autopsy in all cases. Types of heart defects are listed in Table 3 and classified according to blood oxygen supply to the brain. Thirteen (87%) of the 15 cases had low or intermediate oxygen supply to the brain and were classified as CHD Group 1 or 2.
In the frontal cortex, no significant differences in mRNA expression of HIF-1α, HIF-2α, VEGF-A or PlGF were observed between CHD fetuses and controls; however, sFlt-1 expression was 48% higher in CHD fetuses compared with controls (P = 0.0431) (Figure 1a ). In the basal ganglia, significantly higher expression of HIF-2α (98%, P = 0.0456), VEGF-A (60%, P = 0.0432) and sFlt-1 (72%, P = 0.0369) was observed in CHD fetuses compared with controls. No significant differences were observed in the expression of HIF-1α or PIGF between the two groups (Figure 1b) .
DISCUSSION
This study presents the first evidence of abnormal angiogenesis in the brain of human fetuses with CHD. Our findings showed that sFlt-1 expression was higher in both the frontal cortex and the basal ganglia of CHD fetuses compared with controls, while VEGF-A was upregulated in the basal ganglia of CHD fetuses. Moreover, higher HIF-2α expression was observed in the basal ganglia of CHD fetuses compared with controls, probably as a consequence of chronic hypoxia.
In fetuses with CHD, neurological impairment is thought to be a consequence of diminished oxygen distribution and blood flow to the brain caused by abnormal heart morphology. In the third trimester of pregnancy, CHD fetuses have significant differences in head biometry, brain perfusion, cortical development and brain metabolism in comparison with normal fetuses, with signs of severe alterations and an expected severe reduction in oxygenated blood supply to the brain 25 . Moreover, in the second trimester of pregnancy, smaller head biometry was observed in fetuses with all types of CHD. This smaller biometry persisted until the end of pregnancy and did not worsen with advancing gestational age 12, 26 , suggesting that the cause of abnormal brain development could be present at the beginning of pregnancy. In fact, Abu-Rustum et al. reported that alterations of head volume could be detected as early as 11-14 weeks of gestation in fetuses with CHD 28 . Although the smaller head biometry was more pronounced in fetuses with CHD that had compromised blood delivery to the brain, it was also present in those with milder forms of CHD 12, 25, 26 , suggesting that different pathogenic pathways could be involved in prenatal abnormal brain development in CHD fetuses. All CHD cases in the present study had major congenital heart abnormalities that determined the parents' decision to terminate the pregnancy. However, only half of the cases had severe diminished oxygen supply to the brain, indicating that compromised blood delivery to the brain is not the only explanation for our findings.
Alternatively, we can hypothesize that there may have been an intrinsically abnormal vessel formation in our cases. The overproduction of sFlt-1 observed in our CHD fetuses suggests that some degree of antiangiogenic status existed in both of the brain regions studied, which could lead to abnormal vessel formation and ramification in the brain of CHD fetuses. A model of conditional inactivation of VEGF in the embryonic mouse brain revealed that, via local secretion by neural progenitors and/or neurons 29 , VEGF induces brain angiogenesis and provides instructive signals for the correct spatial organization of the vasculature 20 . Moreover, in a murine cerebral infarction model, an upregulation of mRNA and protein levels of VEGF and PlGF was found in different cell types 30 . The neuroprotective effects of PlGF were also observed in an in-vitro rat model of cerebral ischemic injury 31 . Recently, Luna et al. showed that PlGF deficiency was associated with impaired cerebral vascular development in a PlGF −/− mouse model 21 . Although no information on brain histology was obtained in the present study, which could limit the interpretation of our findings, previous studies provide indirect support. Donofrio and Massaro stated that acquired brain injury in CHD may be related to an abnormality in brain development, as suggested by the difference between brain lesions in neonates with CHD and in those with sustained hypoxic ischemic injury 32 . Moreover, it has been hypothesized that altered brain development due to CHD may increase vulnerability to perioperative hemodynamic instability and intraoperative brain injury due to hypoxia and ischemia 33 . Taken together, these findings lead us to speculate that abnormal vessel formation is a common feature in all systems in fetuses with CHD, including the heart, brain and placenta.
We also found that mRNA expression of VEGF-A was significantly higher in the basal ganglia of CHD fetuses compared with controls. Previous studies demonstrated the importance of a tight regulation of VEGF-A expression during cardiac development 34 . VEGF-A expression is controlled and stimulated under hypoxic conditions through both transcriptional and post-transcriptional mechanisms 35, 36 . In the present study, hypoxia in the brain of CHD fetuses was evaluated by analyzing the expression of HIF-1α and HIF-2α factors. Although no differences were found in HIF-1α expression, expression of HIF-2α, a marker of chronic hypoxia, was upregulated in the basal ganglia. This finding is in line with the results of Glauser et al., according to which 45% of babies with hypoplastic left heart syndrome had hypoxic ischemic lesions and/or intracranial hemorrhage 37 . Moreover, previous in-vitro studies demonstrated that HIF-2α preferentially activates VEGF expression 38 . In our study, the increased expression of hypoxia-inducible genes is consistent with hemodynamic Doppler studies showing that a certain degree of cerebral hypoxia might be present in fetuses with CHD 26 . Based on our findings and those of others 18, 19, 39, 40 , we can speculate that CHD fetuses may have an intrinsic altered placentation that may cause a certain degree of fetal hypoxia potentially related to abnormal heart and brain development. Nevertheless, our findings on the expression of angiogenic factors in cerebral tissue showed that although hypoxia may have induced angiogenesis, PIGF was not overexpressed, as we would have expected, whereas high levels of sFlt-1 were found in both the frontal cortex and the basal ganglia, seemingly independent of hypoxia gene expression. These findings are in line with our previous findings in the heart and blood of fetuses with CHD 19 . Taken together, these results suggest that abnormal angiogenesis could be one of the intrinsic pathogenic pathways leading to abnormal brain and heart development.
To the best of our knowledge, this is the first study that has investigated the molecular mechanisms underlying angiogenesis in CHD fetuses. Our results suggest that CHD is associated with intrinsic angiogenic impairment and chronic hypoxia in the fetal brain. Our findings are in agreement with those of observational studies 41 showing abnormal prenatal neurological risk factors in CHD. Further studies are warranted to clarify the extent to which angiogenesis is involved in the brain development of CHD fetuses. 
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